PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT
申请人:Kyorin Pharmaceutical Co., Ltd.
公开号:EP2168959A1
公开(公告)日:2010-03-31
It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action:
wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents:
and BB represents:
wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.
HARTMANN, R. W.;SCHWARZ, W.;SCHOENENBERGER, H., J. MED. CHEM., 1983, 26, N 8, 1137-1144
作者:HARTMANN, R. W.、SCHWARZ, W.、SCHOENENBERGER, H.
DOI:——
日期:——
Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 1. Synthesis and estrogen receptor binding affinity of 2,2'- and 3,3'-disubstituted hexestrols
作者:Rolf W. Hartmann、Walter Schwarz、Helmut Schoenenberger
DOI:10.1021/jm00362a010
日期:1983.8
diastereomers. The bindingaffinity of these compounds to the calf uterine estrogen receptor was measured relative to that of [3H]estradiol by a competitive binding assay. All test compounds showed relative bindingaffinity (RBA) values between 32 and less than 0.01% that of estradiol. Only meso-3,4-bis(2,4-dihydroxyphenyl)hexane (16) showed an estrogen receptor bindingaffinity comparable to that